Standout Papers

Atezolizumab, an Anti–Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Te... 2016 2026 2019 2022 405
  1. Atezolizumab, an Anti–Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study (2016)
    David F. McDermott, Jeffrey A. Sosman et al. Journal of Clinical Oncology

Immediate Impact

2 by Nobel laureates 24 from Science/Nature 74 standout
Sub-graph 1 of 22

Citing Papers

Cancer biomarkers: Emerging trends and clinical implications for personalized treatment
2024 Standout
Immune checkpoint therapy—current perspectives and future directions
2023 StandoutNobel
4 intermediate papers

Works of Yan V. Wang being referenced

A phase Ib/II study of the anti-CD47 antibody magrolimab with cetuximab in solid tumor and colorectal cancer patients.
2020
Atezolizumab, an Anti–Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study
2016 Standout

Author Peers

Author Last Decade Papers Cites
Yan V. Wang 271 522 159 253 8 859
Steven E. Kalloger 226 342 65 312 9 755
Youn Choi Park 606 539 157 58 13 1.0k
AA Bartolucci 165 240 222 186 20 851
Pamela Salman 172 592 235 170 19 962
Jo Marie Tran Janco 80 371 148 363 13 853
DavidA. Clark 445 408 58 268 6 886
Mindert Krans 88 217 225 97 19 1.0k
Miller Ls 106 447 137 121 9 1.0k
Steve Gyorffy 219 251 142 190 18 782
Huiying Piao 195 439 123 97 10 1.1k

All Works

Loading papers...

Rankless by CCL
2026